Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
European Urology Focus|July 30, 2017
Management of Radiologically Indeterminate Magnetic Resonance Imaging Signals in Men at Risk of Prostate CancerEsmée C A van der Sar, Veeru Kasivisvanathan, Mrishta Brizmohun, et al.
Pharmaceutics|June 2, 2021
Competition ('Steal' Phenomenon) between [68Ga]Ga-PSMA-11 Uptake in Prostate Tumor Tissue Versus Healthy TissueEsmée C A van der Sar, Bart de Keizer, Marnix G E H Lam, et al.
Nederlands Tijdschrift Voor Geneeskunde|January 12, 2023
[PSMA PET, an important addition in prostate cancer diagnostics]Esmée C A van der Sar, Jules Lavalaye, Arthur J A T Braat, et al.
Biomedicines|July 27, 2022
Baseline Imaging Derived Predictive Factors of Response Following [177Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based AnalysisEsmée C A van der Sar, Adinda J S Kühr, Sander C Ebbers, et al.
Medical Physics|April 24, 2023
Impact of uptake time on image quality of [68 Ga]Ga-PSMA-11 PET/CTEsmée C A van der Sar, Sebastiaan L Meyer Viol, Arthur J A T Braat, et al.
Insights Into Imaging|August 13, 2022
Cost-effectiveness of the implementation of [68Ga]Ga-PSMA-11 PET/CT at initial prostate cancer stagingEsmée C A van der Sar, Willem R Keusters, Ludwike W M van Kalmthout, et al.
BMC Cancer|March 24, 2023
Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial)Esmée C A van der Sar, Arthur J A T Braat, Jochem R N van der Voort-van Zyp, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 27, 2026
PROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancerLotte G Zuur, Denise S Hoogenkamp, Esmée C A van der Sar, et al.
Pageof 1